BR0115847A - Adenosine Receptor Specific Compounds a1, a2a, and a3 and Uses - Google Patents
Adenosine Receptor Specific Compounds a1, a2a, and a3 and UsesInfo
- Publication number
- BR0115847A BR0115847A BR0115847-3A BR0115847A BR0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A BR 0115847 A BR0115847 A BR 0115847A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- specific compounds
- adenosine receptor
- receptor specific
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"COMPOSTOS ESPECìFICOS PARA RECEPTOR PARA ADENOSINA A~ 1~, A~ 2A~, E A~ 3~ E USOS DOS MESMOS". A invenção diz respeito aos compostos que inibem especificamente os receptores para adenosina A~ 1~, A~ 2A~, e A~ 3~ e ao uso destes compostos para tratar uma doença associada com os receptores para adenosina A~ 1~, A~ 2A~, e A~ 3~ em um paciente, compreendendo administrar ao paciente uma quantidade terapeuticamente efetiva dos compostos."SPECIFIC ADENOSINE RECEIVER COMPOUNDS A ~ 1 ~, A ~ 2A ~, AND A ~ 3 ~ AND USES". The invention relates to compounds which specifically inhibit adenosine receptors A ~ 1 ~, A ~ 2A ~, and A ~ 3 ~ and the use of these compounds to treat a disease associated with adenosine receptors A ~ 1 ~, A ~ 2A1, and A3-3 in a patient, comprising administering to the patient a therapeutically effective amount of the compounds.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
| US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
| PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0115847A true BR0115847A (en) | 2004-02-25 |
Family
ID=27419112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0115847-3A BR0115847A (en) | 2000-12-01 | 2001-11-30 | Adenosine Receptor Specific Compounds a1, a2a, and a3 and Uses |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1347980A4 (en) |
| JP (1) | JP4579497B2 (en) |
| CN (1) | CN1263757C (en) |
| AP (1) | AP1893A (en) |
| AU (1) | AU2002248151B2 (en) |
| BR (1) | BR0115847A (en) |
| CA (1) | CA2430577A1 (en) |
| CZ (1) | CZ20031831A3 (en) |
| EA (1) | EA007254B1 (en) |
| HU (1) | HUP0400692A3 (en) |
| IL (1) | IL155962A0 (en) |
| ME (1) | MEP35308A (en) |
| MX (1) | MXPA03004717A (en) |
| NO (1) | NO327207B1 (en) |
| NZ (1) | NZ525885A (en) |
| OA (1) | OA13295A (en) |
| PL (1) | PL363245A1 (en) |
| WO (1) | WO2002057267A1 (en) |
| YU (1) | YU42703A (en) |
| ZA (1) | ZA200303729B (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
| BR9911612A (en) | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Pyrrole [2,3d] pyrimidine compositions and their uses |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| DE10148883A1 (en) | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors |
| AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| EP2198867A1 (en) * | 2001-12-07 | 2010-06-23 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as GSK-3 inhibitors |
| ATE458483T1 (en) | 2001-12-20 | 2010-03-15 | Osi Pharm Inc | SELECTIVE PYRIMIDINE A2B ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE |
| CN101973998A (en) | 2001-12-20 | 2011-02-16 | Osi药物公司 | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| EP1556053A4 (en) * | 2002-10-31 | 2006-04-19 | Amgen Inc | Antiinflammation agents |
| HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (en) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES |
| EP2043655A2 (en) | 2006-04-25 | 2009-04-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
| JP4705695B2 (en) | 2007-10-11 | 2011-06-22 | アストラゼネカ アクチボラグ | Pyrrolo [2,3-D] pyrimidine derivatives as protein kinase B inhibitors |
| AR070127A1 (en) | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
| KR20100116607A (en) | 2008-01-11 | 2010-11-01 | 낫코 파마 리미티드 | Novel pyrazolo [3,4-d] pyrimidine dericatives as anti-cancer agents |
| PL2694056T3 (en) | 2011-04-01 | 2020-03-31 | Astrazeneca Ab | Therapeutic treatment |
| EP2785349B2 (en) | 2011-11-30 | 2022-11-09 | Astrazeneca AB | Combination treatment of cancer |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
| MX2014014832A (en) * | 2012-06-07 | 2015-02-12 | Hoffmann La Roche | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase. |
| CA2915561C (en) | 2013-06-21 | 2020-09-22 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| WO2015002754A2 (en) | 2013-06-21 | 2015-01-08 | Zenith Epigenetics Corp. | Novel bicyclic bromodomain inhibitors |
| CN105593224B (en) | 2013-07-31 | 2021-05-25 | 恒元生物医药科技(苏州)有限公司 | Novel quinazolinones as bromodomain inhibitors |
| EP3227281A4 (en) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
| WO2016097863A1 (en) | 2014-12-17 | 2016-06-23 | Zenith Epigenetics Corp. | Inhibitors of bromodomains |
| KR101864561B1 (en) * | 2015-01-20 | 2018-06-04 | 우시 포춘 파마슈티컬 컴퍼니 리미티드 | JAK inhibitors |
| CA2982493C (en) | 2015-04-29 | 2020-01-07 | Hao Wu | Jak inhibitors |
| PT3305788T (en) | 2015-05-29 | 2020-09-25 | Wuxi Fortune Pharmaceutical Co Ltd | Janus kinase inhibitor |
| CN105771672B (en) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method |
| CN108570054B (en) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
| CN108017584B (en) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3Small molecule antagonists of adenosine receptors |
| CN110128316B (en) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | Preparation method of 5-substituted beta-proline and derivatives thereof |
| CN110272373B (en) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | Selective adenosine A 1 Receptor antagonists and uses thereof |
| CN114085178A (en) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL176526B1 (en) * | 1992-12-17 | 1999-06-30 | Pfizer | Pyrolopyrimidines as compounds acting as antagonists of corticotrophin releasing factor |
| US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
| BR9911612A (en) * | 1998-06-02 | 2001-02-06 | Osi Pharm Inc | Pyrrole [2,3d] pyrimidine compositions and their uses |
| AU784878B2 (en) * | 1999-12-02 | 2006-07-13 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof |
| AU2002360436A1 (en) * | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
-
2001
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1347980A4 (en) | 2005-02-09 |
| AU2002248151B2 (en) | 2008-02-21 |
| CN1263757C (en) | 2006-07-12 |
| JP2004517896A (en) | 2004-06-17 |
| EA200300628A1 (en) | 2003-12-25 |
| MEP35308A (en) | 2011-02-10 |
| PL363245A1 (en) | 2004-11-15 |
| IL155962A0 (en) | 2003-12-23 |
| NO327207B1 (en) | 2009-05-11 |
| JP4579497B2 (en) | 2010-11-10 |
| YU42703A (en) | 2006-03-03 |
| AP2003002807A0 (en) | 2003-06-30 |
| NO20032482D0 (en) | 2003-06-02 |
| HUP0400692A3 (en) | 2007-09-28 |
| WO2002057267A1 (en) | 2002-07-25 |
| CZ20031831A3 (en) | 2004-05-12 |
| NO20032482L (en) | 2003-07-28 |
| EA007254B1 (en) | 2006-08-25 |
| AP1893A (en) | 2008-09-23 |
| EP1347980A1 (en) | 2003-10-01 |
| CN1489590A (en) | 2004-04-14 |
| CA2430577A1 (en) | 2002-07-25 |
| HUP0400692A2 (en) | 2004-07-28 |
| OA13295A (en) | 2007-04-13 |
| ZA200303729B (en) | 2004-05-14 |
| NZ525885A (en) | 2005-01-28 |
| MXPA03004717A (en) | 2004-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0115847A (en) | Adenosine Receptor Specific Compounds a1, a2a, and a3 and Uses | |
| BR0309544A (en) | Pharmaceutical preparation containing oxycodone and naloxone | |
| AR023715A1 (en) | PHARMACEUTICAL COMPOSITION FOR A SUBJECT WHO NEEDS AN ELEVATION OF THE CONTENT OF NAD INTRACELLULAR, AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE TO INCREASE THE PROTECTIVE CELLULAR RESPONSES TO GENOTOXIC STRESS IN THE SKIN | |
| BR0213358A (en) | Flibanserin use | |
| BR0112476A (en) | Use of dopamine d2 / d3 receptor agonists to treat fibromyalgia | |
| BR0011856A (en) | N-pyrazole a2a receptor agonists | |
| BR9910035A (en) | Guanidine derivatives | |
| BR0309855A (en) | Carbamate substituted pyrazolpyridines | |
| BR0108977A (en) | Azacyclic compounds for use in the treatment of serotonin-related diseases | |
| BR0015974A (en) | Use of levetiracetam, pharmaceutical composition, use of a pharmaceutical composition and methods to treat a patient administered with an amount of at least one compound and a disease and to selectively potentiate the therapeutic effect of a compound | |
| BR0011854A (en) | A2a c-pyrazole receptor agonists | |
| FI920026A0 (en) | PHARMACEUTICAL COMPOSITION ANVAENDBAR SOM AVMAGRINGSMEDICIN. | |
| BR0115109A (en) | Therapeutic agents and methods of their use for angiogenesis modulation | |
| BR0014525A (en) | Process of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | |
| BRPI0007487B8 (en) | diphenyl-ureas substituted with w-carboxy-aryls as raf kinase inhibitors | |
| AR015493A1 (en) | CYCLHEXILOS DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF A USEFUL COMPOSITION TO INHIBIT THE IN VITRO ACTIVITY OF NEURAMINIDASE AND FOR THE TREATMENT OR PROFILAXIS OF INFLUENZA INFLUENZA AND FOR THE PROCESSING AND PROCESSING | |
| AR052921A1 (en) | USE OF RANOLAZINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION | |
| BR0109850A (en) | Combination therapeutic product, pharmaceutical composition, use of a combination therapeutic product, and method for the treatment or prophylaxis of prostate cancer | |
| ES2164040T1 (en) | USE OF AGONISTS OF THE GLICINE UNION SITE OR INHIBITORS OF GLYCIN ABSORPTION FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS. | |
| BRPI0507604A (en) | medicines with hm74a receptor activity | |
| SE0002754D0 (en) | New pharmaceutical combination formulation and method of treatment with the combination | |
| BR0111913A (en) | Gabapentin analogs for sleep disorders | |
| BR0110968A (en) | Il-8 Receptor Antagonists | |
| BR0009524A (en) | Use of a compound, and, pharmaceutical or veterinary composition | |
| BR0316042A (en) | Kits containing body compress and releasably fixable thermal device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |